M&A Deal Summary |
|
|---|---|
| Date | 2018-01-31 |
| Target | STAT-Dx Life S.L. |
| Sector | Medical Products |
| Buyer(s) | Qiagen N.V |
| Deal Type | Add-on Acquisition |
| Deal Value | 191M USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1984 |
| Sector | Life Science |
| Employees | 5,200 |
| Revenue | 1.5B USD (2019) |
QIAGEN N.V. is a Netherlands holding company publically traded on NASDAQ and Frankfurt Prime Standard. The Company is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular insights. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Qiagen was founded in 1986 and is based in Venlo, the Netherlands.
| DEAL STATS | # |
|---|---|
| Overall | 12 of 17 |
| Sector: Medical Products M&A | 3 of 4 |
| Type: Add-on Acquisition M&A Deals | 11 of 16 |
| Country: Spain M&A | 1 of 1 |
| Year: 2018 M&A | 1 of 1 |
| Size (of disclosed) | 2 of 10 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-01-09 |
OmicSoft
Cary, North Carolina, United States OmicSoft Corp. is a provider of multi-omics data management infrastructure solution as well as expertly curated ‘omics’ data sets that complement QIAGEN’s bioinformatics portfolio that are relied upon by customers worldwide to gain valuable insights into complex biological data. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-01-07 |
N-of-One
Concord, Massachusetts, United States N-of-One, Inc. is a provider in clinical interpretation of molecular tests in oncology. N-of-One solutions can standardize and accelerate genomic clinical interpretation and molecular decision support while saving time and money. N-of-One, Inc. was founded in 2008 and is based in Concord, Massachusetts. |
Buy | - |
